文献速递血栓与止血

血小板生成素受体激动剂治疗化疗所致血小板减少症

How I treat chemotherapy-induced thrombocytopenia with thrombopoietin receptor agonists.
PubMed 文献 · Blood · 2026-01-01

化疗所致血小板减少症(CIT)可致严重出血并降低化疗相对剂量强度,目前尚无广泛获批疗法。romiplostim与avatrombopag的全球关键III期临床试验已完成,并有其他试验和观察性研究支持。本文通过4例患者病例,阐述CIT的2种临床亚型(持续性及最低点型),并详述TPO-RA的患者选择、给药、滴定及监测策略。

要点

  • 并非所有CIT患者均需治疗,需识别持续性及最低点型两种亚型。
  • 血小板输注和抗纤溶药在CIT中作用有限。
  • TPO-RA使用需规范选择患者、给药、滴定及监测。

核心结论

  • TPO-RA(romiplostim和avatrombopag)已完成CIT全球关键III期临床试验,为CIT管理提供支持证据。
  • CIT管理需理解持续性及最低点型两种亚型,并明确TPO-RA的适用时机与方式。

研究设计与样本

  • 本文为基于已发表研究及广泛临床经验的叙述性综述,以4例CIT患者病例说明临床常见及挑战性场景。

主要发现

  • CIT是癌症治疗常见并发症,可导致严重出血事件及化疗相对剂量强度降低。
  • 目前尚无广泛可用的获批疗法用于管理CIT。
  • romiplostim和avatrombopag在CIT中的全球关键III期临床试验已完成,并有其他临床试验和观察性研究的额外支持证据。

关键数值与推荐

  • CIT分为持续性及最低点型两种临床亚型。
  • 血小板输注和抗纤溶药在CIT中作用有限。

临床怎么用

  • 并非所有CIT患者需要治疗,应识别需治疗者。
  • 使用TPO-RA时需注重患者选择、给药、滴定及监测。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Chemotherapy-induced thrombocytopenia (CIT) is a common complication of cancer therapy that may result in major bleeding events and reduction of chemotherapy relative dose intensity. Although there remain no widely available licensed therapies to manage CIT, major studies, including global pivotal phase 3 clinical trials of the thrombopoietin receptor agonists (TPO-RAs) romiplostim and avatrombopag in CIT, have been completed, along with additional supporting evidence from other clinical trials and observational studies. As with patients with chemotherapy-induced neutropenia, not all patients with CIT require treatment, but for those who do, it can have a major impact on a patient's oncologic care and outcomes. Proper management of CIT requires an understanding of the 2 clinical subtypes of CIT (persistent and nadir), the limited role of platelet transfusions and antifibrinolytics, and when and how to appropriately use TPO-RA support. In this article, 4 patient cases of CIT are used to illustrate common and challenging scenarios occurring in clinical practice. Built on a framework of published studies and supported by extensive clinical experience, appropriate treatment strategies for CIT are described in detail, with emphasis on proper selection of patient, dosing, titration, and monitoring for the use of TPO-RAs in CIT.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Al-Samkari H, Soff GA. How I treat chemotherapy-induced thrombocytopenia with thrombopoietin receptor agonists. Blood. 2026. PMID: 42406744. doi:10.1182/blood.2026034099

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。